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ABSTRACT.
Purpose: Diabetic retinopathy is the most common eye complication in patients
with diabetes. The purpose of this study is to identify genetic factors contributing
to severe diabetic retinopathy.
Methods: A genome-wide association approach was applied. In the Genetics of
Diabetes Audit and Research in Tayside Scotland (GoDARTS) datasets, cases of
severe diabetic retinopathy were defined as type 2 diabetic patients who were ever
graded as having severe background retinopathy (Level R3) or proliferative
retinopathy (Level R4) in at least one eye according to the Scottish Diabetic
RetinopathyGrading Scheme or who were once treated by laser photocoagulation.
Controlswerediabetic individualswhose longitudinal retinopathyscreeningrecords
were either normal (LevelR0) or onlywithmild background retinopathy (Level R1)
in both eyes. Significant Single Nucleotide Polymorphisms (SNPs) were taken
forward for meta-analysis using multiple Caucasian cohorts.
Results: Five hundred and sixty cases of type 2 diabetes with severe diabetic
retinopathy and 4,106 controls were identified in the GoDARTS cohort. We
revealed that rs3913535 in the NADPH Oxidase 4 (NOX4) gene reached a p
value of 4.05 3 109. Two nearby SNPs, rs10765219 and rs11018670 also
showed promising p values (p values = 7.41 3 108 and 1.23 3 108, respec-
tively). In the meta-analysis using multiple Caucasian cohorts (excluding
GoDARTS), rs10765219 and rs11018670 showed associations for diabetic
retinopathy (p = 0.003 and 0.007, respectively), while the p value of rs3913535
was not significant (p = 0.429).
Conclusion: This genome-wide association study of severe diabetic retinopathy
suggests new evidence for the involvement of the NOX4 gene.
Key words: diabetes – diabetic complications – diabetic retinopathy – genome-wide association
study – NOX4
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Introduction
Diabetic retinopathy (DR) is a chronic,
progressive, potentially sight-threaten-
ing disease of the retinal microvascula-
ture associated with pathophysiological
changes intensiﬁed by diabetes (The
Royal College of Ophthalmologists.
Diabetic Retinopathy Guidelines 2012).
It is the most common eye complica-
tion in diabetic patients and the most
common cause of blindness among
people of working age in the UK
(Bunce & Wormald 2008). In general,
DR can be broadly graded as non-
proliferative diabetic retinopathy
(NPDR) and proliferative diabetic
retinopathy (PDR) according to the
absence or presence of abnormal new
vessels (Williams et al. 2004). In each
year, around 60% of diabetic patients
under retinal screening have NPDR
and approximately 20% of diabetic
patients have active or regressed PDR
(Keenan et al. 2013). It is estimated
that over 1000 new cases of blindness
are caused by DR each year in England
alone and a further 4000 people each
year in the country are thought to be at
risk of vision loss due to retinopathy
(www.diabetes.co.uk 2017). Around
one in ﬁve type 2 diabetic patients in
Scotland have been diagnosed with
DR, and 10% of these DR patients
need to be referred to ophthalmologists
for further treatment (Looker et al.
2012). The quality of life can be signif-
icantly aﬀected for DR patients due to
visual impairment, worries and move-
ment restrictions (Woodcock et al.
2004). In addition to physical and
emotional impacts, DR also represents
a signiﬁcant economic burden to the
healthcare system. In the USA, the
total direct medical cost of DR in
adults was estimated to be $493 million
per year (Rein et al. 2006). The average
annual healthcare costs of NPDR and
PDR per person were €26 and €257 in
Sweden, respectively (Heintz et al.
2010). In addition to the fact that there
is a huge cost diﬀerence depending on
the severity of DR, It has been esti-
mated that without treatment for PDR,
50% of all patients will become blind
within 5 years following diagnosis
(Williams et al. 2004). Therefore, it is
essential to identify and treat this
disorder at an early stage and slow or
stop its progress.
Epidemiological studies have pro-
posed multiple risk factors associated
with the development and the progres-
sion of DR from longitudinal studies
including higher glycaemia, higher
blood pressure, no smoking, male sex,
higher HbA1c, longer duration of dia-
betes, lower body mass index and
elevated blood urea concentration
(Stratton et al. 2001; Xu et al. 2012).
In addition, Xu et al. (2012) reported
that patients with microalbuminuria
were 4.7 times more likely to have a
severe or proliferating DR than those
without microalbuminuria. This study
links DR with renal function since both
DR and diabetic nephropathy are
microvascular complications of dia-
betes. As most of these risk factors
are amenable, clinical trials have been
performed to intervene with the inci-
dence and progress of DR. It is
reported that intensive blood sugar
control eﬀectively delays the onset
and slows the progression of DR when
initiated in adolescent subjects (Dia-
betes & Complications 1994; White
et al. 2001). The persistent beneﬁcial
eﬀect in DR in the intensive therapy
group continues for at least 10 years
(White et al. 2008). Epidemiological
studies are one of the essential tools
to identify risk factors and eﬀective
preventive strategies for diseases along
with genetic studies which search for
underlying causative biological mecha-
nisms and genetic pathways.
Understanding the genetic factors
associated with DR would assist in
identifying biological underpinnings
and potentially suggest molecular tar-
gets for pharmacological research.
Both twin studies and family studies
have conﬁrmed that DR is a heritable
trait in both type 1 and type 2 diabetes
(Leslie & Pyke 1982; Rema et al. 2002;
Hallman et al. 2005; Looker et al.
2007; Monti et al. 2007; Zhang et al.
2010). In particular, a greater genetic
component exists in more severe types
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of DR (Hallman et al. 2005). The
heritability of DR has been estimated
to be 18% in sibling samples (Looker
et al. 2007). Genome-wide linkage
studies have proposed multiple chro-
mosome loci to be linked with DR
using multiple ethnic groups, while no
speciﬁc genes have been identiﬁed
(Imperatore et al. 1998; Hallman et al.
2007; Looker et al. 2007). Candidate
gene approaches have suggested
promising genes with possible biologi-
cal connections with DR such as
VEGFA, AKR1B1, AGER, ICAM1,
MTHFR, while larger samples will be
required to further consolidate the
reliability of these results (Awata et al.
2002; Lindholm et al. 2006; Abhary
et al. 2010; Sim~oes et al. 2014; Opa-
trilova et al. 2017).
Genome-wide association studies
(GWAS) have been very successful in
identifying potential candidate genes
for common complex disorders using
DNA chips (McCarthy et al. 2008).
Recently, several GWAS have pro-
posed multiple susceptibility loci for
DR. However, none of these loci
achieved genome-wide signiﬁcance,
and none have been replicated by other
studies (Fu et al. 2010; Grassi et al.
2011; Huang et al. 2011; Sheu et al.
2013; Burdon et al. 2015).
To facilitate identiﬁcation of the
genetic factors associated with severe
DR, we performed this GWAS using a
homogenous Scottish diabetic popula-
tion in the ﬁrst stage and multiple
Caucasian DR cohorts in the replica-
tion stage. To our knowledge, this is
the ﬁrst GWAS based on Scottish
Diabetic Retinopathy Grading
Scheme and the largest GWAS on
severe DR so far.
Patients and Methods
Participants In the discovery cohort
The datasets from the GoDARTS
project were analysed in this study.
The GoDARTS project mainly recruits
type 2 diabetic patients and non-
diabetic controls throughout Tayside,
Scotland, to identify genetic suscepti-
bility to diabetes including its compli-
cations and response to treatment.
Participants will undertake a simple
baseline clinical examination and com-
plete a lifestyle questionnaire in addi-
tion to providing biological samples
such as blood and urine. The
participants provide informed consent
at the time of recruitment which allows
the use of their data and samples
(including extracted DNA) for research
purposes as well as link the data
anonymously to their medical records.
These records include the Scottish Care
Information-Diabetes Collaboration
(SCI-DC) and Scottish Diabetic
Retinopathy Screening Collaborative
electronic health records used by health
care professionals throughout Scotland
for the care of patients with diabetes.
Further information, including data
access procedures, can be found at
http://diabetesgenetics.dundee.ac.uk/.
The GoDARTS study has been
approved by Tayside Committee on
Medical Research Ethics, and informed
consent was obtained from all patients
(REC reference 053/04). The research
adhered to the tenets of the Declara-
tion of Helsinki.
So far, the project has recruited
9,439 diabetic patients and 6,927 of
them have been genotyped. For this
study, we extracted the DR screening
records of all GoDARTS individuals
from June 1996 until June 2011 as well
as information on age, gender, body
mass index (BMI), HbA1c and dura-
tion of diabetes.
DR grading in Scotland
Retinal screening has been undertaken
in Tayside since 1990, and the DR
screening protocol has previously been
described (Leese et al. 2005). Accord-
ing to the Scottish Diabetic Retinopa-
thy Grading Scheme, DR status can be
graded into ﬁve levels: level R0: No
DR; level R1: mild background
retinopathy; level R2: moderate back-
ground retinopathy; level R3: severe
background retinopathy; level R4:
PDR. The detailed diagnostic criteria
are summarized in Liu et al. (2013)’s
paper. In addition, the status of macula
was recorded as with or without dia-
betic maculopathy. However, the status
of the macula was not taken into
account in this study when deﬁning
DR. The history of laser photocoagu-
lation treatment was also recorded for
GoDARTS participants but lacking
information of the exact methods (pan-
retinal photocoagulation, focal photo-
coagulation or both).
There are other DR grading systems
such as Early Treatment Diabetic
Retinopathy Study (ETDRS), American
Academy of Ophthalmology (AAO)
and National Screening Committee
(NSC). The approximate equivalence
of Scottish Diabetic Retinopathy
Grading Scheme and alternative classi-
ﬁcation systems for diabetic retinopa-
thy can be found in the latest DR
guideline from The Royal College of
Ophthalmologists (The Royal College
of Ophthalmologists 2012).
Definition of severe diabetic retinopathy
cases and controls in GoDARTS
A severe DR case was deﬁned in this
study as a type 2 diabetic individual
with at least one eye that has previously
been coded as severe background
retinopathy (level R3) or PDR (level
R4); or with a history of laser photo-
coagulation treatment in the e-health
records.
A control was deﬁned as a type 2
diabetic individual with DR longitudi-
nal screening records for both eyes,
which were only graded as normal
(level R0) or mild background
retinopathy (level R1). In addition,
controls had no record of laser photo-
coagulation treatment.
To maintain homogeneous case and
control populations, we removed type
2 diabetic individuals whose severest
DR screening records were moderate
background retinopathy (level R2)
from both cases and controls.
In simple words, this study com-
pared severe DR cases (level R3 and
R4) with controls (level R0 and R1).
DR definitions in the multiple Caucasian
and African American Cohorts
Meta-analyses were performed in four
studies of Caucasian patients with type
2 diabetes (The Scania Diabetes Reg-
istry, The Australian DR Genetics
Case-Control Study, The Blue Moun-
tain Eye Study and Cardiovascular
Health Study 2) and two studies of
Caucasian patients with type 1 diabetes
(The Finnish Diabetic Nephropathy
Study and The Genetics of Kidneys in
Diabetes study/The Epidemiology of
Diabetes Interventions and Complica-
tions). Diabetic retinopathy (DR) was
deﬁned either based on ETDRS scor-
ing, or laser treatment. See the
Appendix S1 for the DR deﬁnitions
for all cohorts. A general description of
all cohorts can also be found in the
Appendix S1.
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Genotyping and quality control
The GoDARTS diabetic individuals
were genotyped by either Aﬀymetrix
SNP6.0 chips (3,673 patients) funded
by the Wellcome Trust Case Control
Consortium 2 (WTCCC2) project or by
Illumina OmniExpress chips (3,254
patients) funded by the Surrogate
markers for Micro- and Macro-vascu-
lar hard endpoints for Innovative dia-
betes Tools (SUMMIT) project.
Standard protocols were used for geno-
typing quality controls for the
WTCCC2 studies and the SUMMIT
studies (GoDARTS and UKPDS Dia-
betes Pharmacogenetics Study Group
et al. 2011; Fagerholm et al. 2012). The
genotyping quality control of other
Caucasian and African American DR
cohorts followed their own protocols.
Statistical analysis
The imputation of non-genotyped single
nucleotidepolymorphisms (SNPs) in the
Aﬀymetrix SNP6.0 chips and Illumina
OmniExpress chips were done by SHA-
PEIT and IMPUTE2 using reference
ﬁles from the 1000 genome phase I
datasets (Howie et al. 2006; Delaneau
et al. 2011). The recommended r2 > 0.3
was used to ﬁlter out badly imputed
SNPs. Routine quality control steps
were frequently applied using PLINK
(removing SNPs with over 5% genotyp-
ing missing, or with minor allele fre-
quency less than 1%, or those that failed
Hardy–Weinberg tests p < 0.000001,
and removing individuals with more
than5%genotypedatamissing) (Purcell
et al. 2007). SNPs on the X and Y
chromosomes and mitochondrial SNPs
were excluded from analyses. Popula-
tion stratiﬁcation analysis was based on
multidimensional scaling integrated in
PLINKtodetect anydiﬀerence in ances-
try within the cohort, with a lambda
value indicating the level of stratiﬁca-
tion. Removal of related samples was
basedonpi-hat> 0.125 in PLINK.Thep
values for SNP associations were gener-
atedbasedonlogisticregressionanalyses
using PLINK, and adjusting for age,
gender, BMI,HbA1c and duration of
diabetes. Ap value of less than 5 9 108
was considered to be an association,
warranting further exploration. The LD
scores (R-squared) among signiﬁcant
SNPs were later calculated by PLINK.
The positive SNPs generated from the
ﬁrst stagewere thenmeta-analysedusing
multiple replication cohorts where p
values of these SNPs were generated by
logistic regression adjusting with rele-
vant covariates. Multiple meta-analyses
were performed by GWAMA combin-
ing Caucasian cohorts and African
American cohorts (M€agi & Morris
2010). SNP functional annotations were
applied by SNPnexus, and the Manhat-
tan plot was generated by HaploView
(Barrett et al. 2005; Dayem Ullah et al.
2013).LocusZoomwasused for regional
visualization (Pruim et al. 2010).
SNPEVG was used to generate the
corresponding Q-Q plot, a tool to eval-
uate diﬀerences between cases and con-
trols caused by potential confounders
(diﬀerentgenotyping lab,diﬀerentDNA
extraction methods, etc) (Wang et al.
2012). Narrow-sense heritability was
calculated by GCTA (Lee et al. 2011).
Means of age, BMI, HbA1c and dura-
tion of diabetes were compared between
cases and controls using independent t
tests in SPSS 22 (IBM Corp, New York,
NY, USA). The gender diﬀerence was
evaluated using Chi-squared test (2 9 2
tables).
Results
In the GoDARTS population, we
identiﬁed 560 unrelated severe DR
patients (133 individuals with severe
background retinopathy and 427 indi-
viduals with PDR) and 4106 controls
(1873 individuals with no DR and
2233 individuals with mild background
retinopathy) based on our deﬁnitions.
The clinical characteristics of cases
and controls are summarized in
Table S1. There are statistical diﬀer-
ences between the cases and the con-
trols in terms of gender, age, duration
of diabetes and HbA1c. There is no
statistical diﬀerence of BMI between
the two groups. Altogether 6 585 471
imputed SNPs passed from routine
quality control checking and imputa-
tion quality score r2 > 0.3. Since the
multidimensional scaling analysis for
population stratiﬁcation found a
lambda value of 1.005 for the cleaned
datasets, no further adjustment based
on population stratiﬁcation was
applied. The corresponding Q-Q plot
is shown in Fig. S1. Using logistic
regression analysis integrated in
PLINK with gender, age, duration of
diabetes andHbA1c as covariates, there
was a cluster appearing in the Manhat-
tan plot (only SNPs with p values less
than 0.01 were used) (Fig. 1). The top
SNP in this region was rs3913535 in the
NOX4 gene with a p value of 4.05 9
109 and an odds ratio (OR) of 1.55
(95% conﬁdence interval: 1.34–1.79).
Two nearby SNPs, rs10765219 and
rs11018670, also showed promising p
values (p = 7.41 9 108, 1.23 9 108,
respectively). Table 1 summarises these
SNPs found in the region. Figure S2
shows the regional plot of the identiﬁed
loci. We downloaded the linkage infor-
mation of these three SNPs from
HapMap Caucasian population and
found the linkage disequilibrium (LD)
scores (R-squared) of these three SNPs
from GoDARTS are quite consistent
with those from HapMap (Table S2).
The heritability of severe DR was esti-
mated to be 7.00% in this diabetic
population based on the restricted max-
imum likelihood analysis by GCTA. In
the replication cohorts, including seven
Caucasian DR cohorts with multiple
DR deﬁnitions, the meta-analysis p
values of rs3913535, rs10765219 and
rs11018670 were 0.429, 0.003 and 0.007,
respectively (Table 2). When combined
with the GoDARTS results, the meta-
analysis p values of these three SNPs
were 0.71, 9.02 9 105 and 4.24 9
104, respectively (Table 2). The forest
plots of these three SNPs in the Cau-
casian DR cohorts are summarized in
Fig. 2. In the four African American
DR cohorts, the meta-analysis p values
of rs3913535, rs10765219 and rs11018670
were 0.883, 0.814 and 0.686, respec-
tively (Table S3).
Discussion
This GWAS on severe DR was based
on a well-deﬁned type 2 diabetic pop-
ulation in the UK and has suggested
new evidence that the NOX4 gene
might be associated with severe DR.
Supporting evidence was also obtained
from multiple Caucasian DR cohorts.
In Scotland, all patients with dia-
betes are invited to have an annual
retinal screening. During the screening,
the clinical information of the eyes is
recorded such as visual acuity (VA),
cataract status, retinal status, macula
status, etc. The severe DR cases in
GoDARTS are a combination of type
2 diabetes patients with severe back-
ground retinopathy and PDR or any-
one with a record of laser
photocoagulation treatment. We have
two reasons for this deﬁnition. First,
Liu et al. (2013) observed that there is
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an accelerated trend from a less severe
DR status to a more severe DR status.
For example, it takes approximately
0.11 years for severe background
retinopathy to progress to PDR, while
it takes 12.6 years from no DR status
to mild background retinopathy. In
other words, most severe background
retinopathy will progress to PDR in a
relatively short timeframe. This is
matched with the fact that there were
more PDR (427 individuals) than sev-
ere background retinopathy (133 indi-
viduals) in the GoDARTS cohort.
Second, Grassi et al. used patients with
PDR and/or diabetic macular oedema
as severe DR cases. Though this case
deﬁnition is stricter, it only left 281
severe cases for their sub-GWAS anal-
ysis on severe DR (Grassi et al. 2011).
Therefore, it is reasonable to use our
deﬁnition to increase case sample size
and correspondingly to increase the
power of this study. Our control
deﬁnition includes DR-free and mild
background retinopathy individuals.
This is based on a phenomenon that
substantial rates of mild background
DR regression can be observed in
longitudinal studies. Diabetic retinopa-
thy (DR) is often observed to regress
from mild background retinopathy to
no DR status, but it is not possible to
revert from PDR to no DR (Liu et al.
2013). Around 50% of type 2 diabetic
patients without DR at baseline will
develop DR ﬁve years later, while 25%
of type 2 diabetic patients with non-
severe DR will fully recover from DR
in the same period (Jin et al. 2014).
Since these patients ﬂuctuate between
DR-free and mild background
retinopathy, it is reasonable to treat
them as one group. Further, the genetic
mechanisms of non-severe DR and
severe DR might not be the same.
Non-severe DR is likely driven by a
microenvironment change in the eye,
while severe DR can be the conse-
quences of the interaction between
genes and the microenvironment in
the eye. In other words, genetics play
a bigger role in severe DR than non-
severe DR (Hallman et al. 2005). The
same phenomenon also happens in
another eye disorder—myopia, for
which low myopia is considered as an
environmental-driven result, while high
myopia is a consequence of both genetic
and environment factors (Meng et al.
2012b). Thus, it is reasonable to use this
control deﬁnition. Nevertheless, our
control population with no severe DR
cases is better than using a population
control which contains a small propor-
tion of severe DR cases. To have homo-
geneous case and control populations,
we also removed moderate background
retinopathy samples from both case and
control populations. In the GWAS
study on type 1 diabetes byGrassi et al.,
all non-severe DR cases were treated as
Fig. 1. Manhattan plot of the GWAS on severe DR using quality-controlled SNPs. X axis represents 22 autosomes. Y axis means the log10 of p
values. The blue line indicates the p value of 107.
Table 1. Top hits of the GWAS on the severe DR in the GoDARTS.
SNPs
Chr:position
(hg19) Gene
Minor allele (its
frequency in
cases:controls) p value OR  SE CI 0.95
Imputation
score (Aﬀymetrix:
Illumina)
rs3913535 11:89096757 NOX4 C (0.518:0.411) 4.05 9 109 1.55  0.07 1.34–1.79 1:0.98
rs10765219 11:89354278 31 kb to NOX4 T (0.529:0.424) 7.41 9 108 1.54  0.08 1.31–1.80 1:0.94
rs11018670 11:89356628 33 kb to NOX4 G (0.534:0.427) 1.23 9 108 1.55  0.08 1.33–1.80 1:0.98
CI = conﬁdence interval, OR  SE = odds ratio  standard error.
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control samples, which means they sup-
port our hypothesis that genetic mech-
anisms of severeDRandnon-severeDR
might not be the same. Similar to Grassi
et al.’s work,we also donot consider the
status of diabetic nephropathy in our
GWAS. We recognize that our case-
control ratio is 1:7 which is consistent
with the case-control ratio of the
UKPDS cohort (R0 = 2,316, R1 +
R2 = 801, R3 + R4 = 509) (Kohner
et al. 2001). It is expected that the
power will not increase dramatically if
the case-control ratio is smaller than
1:4 when the overall sample size
increases (Grimes & Schulz 2005).
But, for GWAS, it is recommended
to have a larger sample size. A good
phenotype deﬁnition will gather rela-
tively homogeneous individuals with
similar clinical conditions and under-
lying genetic mechanisms.
The most signiﬁcant SNP was iden-
tiﬁed in the NOX4 gene with a p value
of 4.05 9 109 at rs3913535 and an
odds ratio (OR) of 1.55 (95% conﬁ-
dence interval: 1.34–1.79). Two nearby
SNPs, located next to NOX4,
rs10765219 and rs11018670 also
showed promising p values (p =
7.41 9 108, 1.23 9 108). The NOX4
gene encodes the NOX4 protein which
is located in non-phagocytic cells where
Table 2. The input information and the output meta-analysis results of 7 Caucasian cohorts based on GWAMA (default setting).
Cohorts MARKER EA NEA OR OR_95L OR_95U N (cases + controls) p
GoDARTS (severe DR, type 2) rs3913535 C T 1.55 1.34 1.79 4666 (560 + 4,106) 4.05 9 109
rs10765219 T G 1.54 1.31 1.80 4666 7.41 9 108
rs11018670 G A 1.55 1.33 1.80 4666 1.23 9 108
SDR (general DR, type 2) rs3913535 C T 0.98 0.95 1.01 2016 (1,151 + 865) 0.25
rs10765219 T G 1.04 1.004 1.07 2016 0.02
rs11018670 G A 1.03 1.004 1.07 2016 0.03
AUST (general DR, type 2) rs3913535 C T 1.05 0.84 1.30 780 (346 + 434) 0.68
rs10765219 T G 1.04 0.84 1.28 780 0.73
rs11018670 G A 1.05 0.85 1.30 780 0.62
BMES (general DR, type 2) rs3913535 C T 1.89 0.90 3.99 162 (15 + 147) 0.09
rs10765219 T G 2.76 1.31 5.79 162 0.007
rs11018670 G A 2.85 1.35 6.02 162 0.006
CHS2 (general DR, type 2) rs3913535 C T 1.12 0.30 4.11 116 (5 + 111) 0.87
rs10765219 T G 1.67 0.47 5.92 116 0.43
rs11018670 G A 1.69 0.48 5.93 116 0.42
FinnDiane (general DR, type 1) rs3913535 C T 1.05 0.92 1.21 2670 (1,638 + 1,032) 0.53
rs10765219 T G 1.13 0.99 1.29 2670 0.08
rs11018670 G A 1.09 0.95 1.23 2670 0.23
GoKinD; EDIC (general DR type 1) rs3913535 C T 1.03 0.91 1.16 2829 (973 + 1,856) 0.52
rs10765219 T G 1.08 0.95 1.22 2829 0.21
rs11018670 G A 1.05 0.91 1.21 2829 0.42
Meta-analysis without GoDARTS rs3913535 C T 0.99 0.96 1.02 8573 (4,128 + 4,445) 0.42
rs10765219 T G 1.05 1.02 1.08 8573 0.003
rs11018670 G A 1.03 1.01 1.06 8573 0.007
Meta-analysis all Caucasian cohorts rs3913535 C T 1.01 0.98 1.03 13 239 (4688 + 8,551) 0.71
rs10765219 T G 1.07 1.03 1.10 13 239 9.02 9 105
rs11018670 G A 1.04 1.02 1.07 13 239 4.24 9 104
AUST = The Australian DR Genetics Case–Control Study, BMES = The Blue Mountain Eye Study, CHS2 = Cardiovascular Health Study 2,
EA = eﬀective allele, EDIC = The Epidemiology of Diabetes Interventions and Complications, FinnDiane = The Finnish Diabetic Nephropathy
Study, GoDARTS = The Genetics of Diabetes Audit and Research Tayside, GoKinD = The Genetics of Kidneys in Diabetes study, N = number,
NEA = non-eﬀective allele, OR = odds ratio, SDR = The Scania Diabetes Registry.
Fig. 2. The forest plots of 3 SNPs in the Caucasian DR cohorts.
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it acts as an oxygen sensor and catal-
yses the reduction of molecular oxygen
to various reactive oxygen species
(ROS). The ROS has been linked with
numerous biological functions includ-
ing signal transduction, cell diﬀerenti-
ation and tumour cell growth (www.
ncbi.nlm.nih.gov/gene/50507 2017).
Nox4 mediates vascular endothelial
growth factor receptor (VEGF) 2-
induced intravitreal neovascularization
in a rat model of retinopathy of
prematurity (Wang et al. 2014). In
mice models, activation of Nox4 plays
an essential role in high-glucose and
hypoxia-mediated VEGF expression
and diabetes-induced blood-retinal
barrier breakdown, while the inhibition
of Nox4 contributes to the protective
eﬀects of lovastatin in diabetic
retinopathy (Li et al. 2010). In addi-
tion, Nox4’s expression is signiﬁcantly
increased in oxygen-induced retinopa-
thy and upregulation of Nox4 con-
tributes to retinal neovascularization
formation in oxygen-induced retinopa-
thy (Li et al. 2014). Further, Nox4 has
been identiﬁed to mediate insulin-sti-
mulated VEGF expression and angio-
genesis in cells (Meng et al. 2012a).
Last but not least, it is also reported
that Nox4-mediated oxidative stress
contributes to Wnt pathway activation
in diabetic retinopathy (Liu et al.
2014). Modulation of retinal Nox4
expression may present a promising
therapeutic approach for neovascular
retinal diseases. In addition to DR,
NOX4 has been linked with other
diabetic microvascular disorders such
as diabetic nephropathy with strong
evidence. Inhibitor of the NOX4 gene
has been proved to have renoprotec-
tion in diabetic nephropathy (Gorin &
Block 2013; Jha et al. 2014; Thallas-
Bonke et al. 2014). The inhibitor, also
named as GKT-137831, has been under
Phase II clinical development for the
treatment of diabetic nephropathy,
though it failed to pass recently (Gorin
et al. 2015). We did not have direct
replications of these 3 SNPs for the
same deﬁnitions of severe DR, but we
have performed a meta-analysis of
these 3 SNPs from multiple Caucasian
DR cohorts including Scania Diabetic
Registry (SDR), Finnish Diabetic
Nephropathy Study (FinnDiane),
Genetics of Kidneys in Diabetes study
(GoKinD), Epidemiology of Diabetes
Interventions and Complications
(EDIC), Australian DR Genetics
Case-Control Study (AUST), The Blue
Mountain Eye Study (BMES) and
Cardiovascular Health Study 2
(CHS2), regardless of the types of
diabetes, the DR grading methods
and the severity of DR (Table 2). The
meta-analysis p values of these SNPs
were no longer GWAS signiﬁcant
though the p values of rs10765219
and rs11018670 were less than 0.01.
This could be due to multiple reasons
such as diﬀerent ethnic populations,
diﬀerent types of diabetes, the hetero-
geneity of DR deﬁnitions, diﬀerent
levels of DR severity in these Cau-
casian DR cohorts and diﬀerent
adjusted covariates (which might lead
to bias) among cohorts (see the
Appendix S1). We also performed a
meta-analysis using four African
American DR cohorts including Afri-
can American Proliferative Diabetic
Retinopathy Study (AAPDR), Jackson
Heart Study (JHS), Atherosclerosis
Risk in Communities (ARIC) Study
and Multi-Ethnic Study of Atheroscle-
rosis-African Americans (MESA-AA).
The three SNPs did not show positive
results (Table S3). The directions of the
eﬀect of these SNPs are quite consis-
tent among Caucasian DR cohorts,
while they were quite mixed among
African American DR cohorts. In
addition to the above-mentioned rea-
sons, the smaller sample size in each
African American cohort could be
causing these mixed directions of eﬀect.
Finally, it is noticed that all the three
SNPs strongly aﬀect the NOX4 gene
expression according to the Genotype-
Tissue Expression (GTEx) portal
though the cells used were from ﬁbrob-
lasts, not from eyes (Carithers et al.
2015).
Narrow-sense heritability of severe
DR was estimated to be 7.00% in this
diabetic population. Narrow-sense her-
itability means the ratio of total phe-
notypic variance that is due to additive
genetic eﬀects (Lee et al. 2011). This
estimation does not include the contri-
bution of gene-gene interactions, gene-
environment interactions, etc, so the
actual heritability of this phenotype is
likely to be greater. We have suggested
that severe DR is a heritable trait in
this GWAS and further genetic
research is warranted.
We had moderate power in this
study due to the limited number of
cases in GoDARTS. According to
CaTS, using an additive model, we
had 80% power to detect a genotypic
relative risk of 1.50 for variants with a
minor allele frequency of 30% when
the disease prevalence in the popula-
tion is 25% and the signiﬁcance level is
5 9 108 (Skol et al. 2006). We also
provided the corresponding p values in
the GoDARTS of the SNPs suggested
by other GWAS studies (Table S4).
For reader’s interest, we also selected
controls with diabetic history over
20 years (N = 470) to perfectly match
cases in terms of duration of diabetes.
The p values of the three SNPs
increased, which were mainly caused
by decreased sample size.
A consensus phenotyping approach
to DR will not only improve data and
study quality but also help to discover
novel mechanisms of DR at a molecu-
lar level. It has the potential for iden-
tifying drug targets and eventually
leading to better therapeutic manage-
ment. This study will initiate more
questions to answer about diabetic
retinopathy, such as 1. Do diabetic
retinopathy and other types of retino-
pathies share common genetic compo-
nents? 2. Are the mechanisms of
diabetic retinopathy in type 1 and type
2 diabetes the same or not?
This analysis suggests new evidence
that NOX4 gene might be associated
with severe DR. We used a novel
approach in this study to deﬁne severe
DR cases and controls, based on DR
screening results and Scottish Diabetic
Retinopathy Grading Scheme to have a
reasonably homogenous phenotype.
Our next step is to attempt replication
of signiﬁcant SNPs using newly
recruited samples and focus on the
molecular mechanisms that may be
responsible for the association hits.
The ﬁndings of these studies will help
to conﬁrm the role of NOX4 in the DR
mechanisms and provide possible drug
targets for DR treatment.
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